Previous Close | 2.0500 |
Open | 2.0500 |
Bid | 1.9800 x 1000 |
Ask | 2.1500 x 1200 |
Day's Range | 1.9800 - 2.0500 |
52 Week Range | 1.9400 - 4.4100 |
Volume | |
Avg. Volume | 223,679 |
Market Cap | 76.109M |
Beta (5Y Monthly) | 2.82 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.7700 |
Earnings Date | Nov 08, 2023 - Nov 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for ATHA
BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in New York City. Details are as follows: 2023 Cantor Fitzgerald Global Healthcare Conferenc
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.